#France #UroMems #Rinda Sama #Grenoble #UroActive

UroMems Welcomes Rinda Sama to Its Board of Directors

UroMems, a global leader in medical technology, has recently announced the appointment of Rinda Sama to its Board of Directors. This strategic move comes as the company prepares to launch crucial clinical trials for its groundbreaking UroActive system, designed to address stress urinary incontinence (SUI) through advanced automated implant technology.

Rinda Sama, a seasoned professional with nearly two decades of experience in the medical device industry, previously served as Chief Operating Officer at Axonics, where she played a pivotal role in streamlining operations and ensuring regulatory compliance. Her expertise in sacral neuromodulation for overactive bladder treatment positions her as a valuable asset to UroMems as it seeks to revolutionize the field of urinary health.

The Strategic Significance of Rinda Sama’s Appointment

As UroMems embarks on extensive clinical studies for its UroActive system, Sama’s input is expected to enhance operational efficiency and accelerate the product's journey through the Food and Drug Administration (FDA) approval process. Hamid Lamraoui, UroMems' co-founder and CEO, expressed enthusiasm about Rinda's addition, highlighting her vast experience in med-tech and regulatory pathways that could significantly benefit the company's innovations.

In her past role at Axonics, Sama was instrumental in developing effective quality management systems that ultimately facilitated FDA approvals and the subsequent acquisition of Axonics by Boston Scientific. Her in-depth understanding of both operational dynamics and clinical requirements makes her ideal for guiding UroMems through its own upcoming challenges.

Moreover, Sama’s academic background, which includes a Master's in Biomedical Engineering from the University of Southern California and an MBA from the University of California, Irvine, further complements her expertise, making her a holistic leader at UroMems.

The UroActive System: A Game-Changer for Urinary Incontinence Treatment

The UroActive system represents a significant leap forward in treating SUI, a condition affecting an estimated 40 million Americans and approximately 90 million Europeans. Traditional treatments often fall short in offering significant relief and patient satisfaction. UroActive is touted as the first active, implantable electronic artificial urinary sphincter, ingeniously designed to adjust to individual patient needs through sophisticated mechatronic systems and patient data analytics.

Once fully operational, the UroActive system aims to provide patients suffering from SUI with a reliable and dynamic treatment option, addressing a previously underserved market. UroMems recently secured $47 million in funding, driven by proactive clinical milestones and promising initial results for its first female patient, marking a hopeful trajectory for its clinical ambitions.

In her statement, Rinda Sama remarked, “UroMems is at a turning point, much like Axonics was years ago when we were championing breakthrough treatments in a stagnant segment. I see tremendous potential in the UroActive system to transform SUI treatment for patients much like we did with the introduction of the first intelligent AUS.”

Conclusion

With Rinda Sama's expertise at the helm, UroMems is poised to not only push the boundaries of current medical innovations in treating urinary incontinence but also to enhance patient outcomes across the globe. As the company gears up for its upcoming clinical trials, the med-tech community eagerly anticipates the potential impact of UroActive and the leadership of Rinda Sama on this promising frontier in health technology. For more information about UroMems and the UroActive system, please visit www.uromems.com.